Paralytic ileus due to a novel anticancer drug, nab‑paclitaxel: A case report

  • Authors:
    • Xiao‑Dong Jiao
    • Xiu Luo
    • Wen‑Xing Qin
    • Ling‑Yan Yuan
    • Yuan‑Sheng Zang
  • View Affiliations

  • Published online on: February 16, 2016     https://doi.org/10.3892/mco.2016.782
  • Pages: 824-826
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Nab‑paclitaxel is a recently emerged chemotherapy drug, which is widely used for the treatment of multiple types of cancer. The prospects of this novel drug are very bright as a result of its higher efficacy and lower toxicity compared with paclitaxel. Hence, the side effect, even if rare, require attention in clinical practice. The present study described an unusual case of nab‑paclitaxel‑associated paralytic ileus. To the best of our knowledge, this is the first report to demonstrate that nab‑paclitaxel may lead to acute intestinal obstruction. Since nab‑paclitaxel will be used more frequently, this unusual side effect might be encountered by a clinical oncologist and must be treated correctly. This is the first reported case, to the best of our knowledge, of paralytic ileus caused by nab‑paclitaxel, which will be widely used as a novel anticancer drug.
View Figures
View References

Related Articles

Journal Cover

May 2016
Volume 4 Issue 5

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Jiao, X., Luo, X., Qin, W., Yuan, L., & Zang, Y. (2016). Paralytic ileus due to a novel anticancer drug, nab‑paclitaxel: A case report. Molecular and Clinical Oncology, 4, 824-826. https://doi.org/10.3892/mco.2016.782
MLA
Jiao, X., Luo, X., Qin, W., Yuan, L., Zang, Y."Paralytic ileus due to a novel anticancer drug, nab‑paclitaxel: A case report". Molecular and Clinical Oncology 4.5 (2016): 824-826.
Chicago
Jiao, X., Luo, X., Qin, W., Yuan, L., Zang, Y."Paralytic ileus due to a novel anticancer drug, nab‑paclitaxel: A case report". Molecular and Clinical Oncology 4, no. 5 (2016): 824-826. https://doi.org/10.3892/mco.2016.782